Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Development of sulfonyl fluoride chemical probes to advance the discovery of cereblon modulatorsElectronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d3md00652b

Autor: Liu, Yingpeng, Nowak, Radosaw P., Che, Jianwei, Donovan, Katherine A., Huerta, Fidel, Liu, Hu, Metivier, Rebecca J., Fischer, Eric S., Jones, Lyn H.

Publikováno v: MedChemComm; 2024, Vol. 15 Issue: 2 p607-611, 5p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Development of a covalent cereblon-based PROTAC employing a fluorosulfate warhead.

Autor: Nowak RP; Center for Protein Degradation, Dana-Farber Cancer Institute Boston MA USA lyn_jones@dfci.harvard.edu nowak@crystal.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School Boston MA USA.; Department of Cancer Biology, Dana-Farber Cancer Institute Boston MA USA., Ragosta L; Center for Protein Degradation, Dana-Farber Cancer Institute Boston MA USA lyn_jones@dfci.harvard.edu nowak@crystal.harvard.edu., Huerta F; Center for Protein Degradation, Dana-Farber Cancer Institute Boston MA USA lyn_jones@dfci.harvard.edu nowak@crystal.harvard.edu., Liu H; Center for Protein Degradation, Dana-Farber Cancer Institute Boston MA USA lyn_jones@dfci.harvard.edu nowak@crystal.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School Boston MA USA., Ficarro SB; Department of Cancer Biology, Department of Oncologic Pathology, and Blais Proteomics Center, and Center for Emergent Drug Targets, Dana-Farber Cancer Institute Boston MA USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School Boston MA 02115 USA., Cruite JT; Center for Protein Degradation, Dana-Farber Cancer Institute Boston MA USA lyn_jones@dfci.harvard.edu nowak@crystal.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School Boston MA USA., Metivier RJ; Department of Cancer Biology, Dana-Farber Cancer Institute Boston MA USA., Donovan KA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School Boston MA USA.; Department of Cancer Biology, Dana-Farber Cancer Institute Boston MA USA., Marto JA; Department of Cancer Biology, Department of Oncologic Pathology, and Blais Proteomics Center, and Center for Emergent Drug Targets, Dana-Farber Cancer Institute Boston MA USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School Boston MA 02115 USA., Fischer ES; Center for Protein Degradation, Dana-Farber Cancer Institute Boston MA USA lyn_jones@dfci.harvard.edu nowak@crystal.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School Boston MA USA.; Department of Cancer Biology, Dana-Farber Cancer Institute Boston MA USA., Zerfas BL; Center for Protein Degradation, Dana-Farber Cancer Institute Boston MA USA lyn_jones@dfci.harvard.edu nowak@crystal.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School Boston MA USA., Jones LH; Center for Protein Degradation, Dana-Farber Cancer Institute Boston MA USA lyn_jones@dfci.harvard.edu nowak@crystal.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School Boston MA USA.

Publikováno v: RSC chemical biology [RSC Chem Biol] 2023 Aug 31; Vol. 4 (11), pp. 906-912. Date of Electronic Publication: 2023 Aug 31 (Print Publication: 2023).